Bristol Myers Squibb
Search results
Learn how Celgene, a global biopharmaceutical company, is committed to improving the lives of patients worldwide by delivering truly innovative and life-changing treatments. Explore the therapies for Hematology, Oncology, Inflammation and Immunology and the medical research to help people live longer, better, and healthier.
Footnotes / references. [1] Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid ( lenalidomide ), which is used in the treatment of multiple myeloma, and also in certain anemias.
Nov 20, 2019 · Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.
Jan 3, 2019 · In connection with the proposed transaction between Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) and Celgene Corporation (“Celgene”), Bristol-Myers Squibb and Celgene will file relevant materials with the Securities and Exchange Commission (the “SEC”), including a Bristol-Myers Squibb registration statement on Form S-4 that ...
Jan 3, 2019 · Drugmaker Bristol-Myers Squibb announced Thursday a $74 billion deal to buy Celgene, in one of the biggest mergers in pharmaceutical industry history. The deal, which still needs the approval of...
Nov 20, 2019 · Bristol-Myers Squibb has completed its $95 billion acquisition of Celgene Corp., a deal announced at the beginning of the year. It is one of the largest acquisitions in pharmaceutical history.
Jan 3, 2019 · Bristol-Myers to Acquire Celgene in Deal Worth $74 Billion. After the deal is completed, expected this year, Bristol-Myers Squibb shareholders will own 69 percent of the combined entity, while ...
